Customize
Quick Links

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 20.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 20.25 Contact Hours.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Accreditation/Credit Designation (CAR T Pre-conference Workshop)

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 3.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, Adaptive Biotechnologies, Bristol-Myers Squibb, and Seattle Genetics, Inc.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma

22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma


Thursday, March 1, 2018 – Sunday, March 4, 2018
The DIPLOMAT
3555 South Ocean Drive
Hollywood, FL 33019
Phone: 954-602-6000
Website: www.diplomatresort.com

Overview

Now in its 22nd year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma facilitates clinicians’ skills to contextualize the wealth of emerging data on how to treat hematologic malignancies, personalize treatment based upon patient and tumor characteristics, and apply novel management strategies to their practices to improve outcomes for their patients.

Back by popular demand! The 3.5 day meeting will be held from Thursday through mid afternoon Sunday. As always, agenda topics will focus on methods to practically apply state-of-the-art strategies to your clinical practice settings. This engaging and highly interactive meeting will provide ample opportunity to interact with renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and benign hematologic malignancies. Our faculty will distill practice-changing evidence and recommend methods to place this information in its proper context and apply it to real-world care scenarios you encounter. In doing so, a focus will be placed on how to proactively mitigate and manage treatment-related toxicities associated with new treatment strategies.

The well-known and highly interactive Medical Crossfire® discussion panels interspersed throughout the meeting will allow attendees to explore some of the most challenging clinical situations in the management of hematologic malignancies, many of which have multiple potential approaches to care.

The case-based format of the Congress will challenge participants to apply new information they have learned, reflect on new practices they can bring back to their clinics to share with their peers, and ultimately improve patient outcomes in their practice settings.
 

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, Adaptive Biotechnologies, Bristol-Myers Squibb, and Seattle Genetics, Inc.

Target Audience

This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.

Learning Objectives

At the conclusion of this Congress, you should be better prepared to:

  • Detail methods by which clinical decision making in the management of hematologic malignancies can be personalized with the use of current and emerging biomarkers
  • Describe recent evidence on methods to optimize outcomes and consider them in the context of evolving treatment pathways and their application to individual patient cases
  • Explain practical methods to proactively mitigate and manage treatment-related toxicities so that optimized outcomes are not compromised in the management of hematologic malignancies
  • Evaluate new mechanistic approaches and compounds undergoing clinical investigation for the management of hematologic malignancies
  • State the therapeutic implications of recent evidence on evolving treatment paradigms for patients with hematologic tumors

Hot Topics for 2018:

  • Key biomarkers to consider in myeloma management
  • CAR-T cells and other immunotherapeutic strategies to treat hematologic malignancies
  • New clinical considerations for frontline and maintenance strategies for follicular lymphoma
  • New chronic lymphocytic leukemia agents: what patient and drug characteristics will inform sequencing decisions in relapsed/refractory disease
  • Novel therapies in acute leukemias and how they may alter treatment standards
  • Paradigm-changing strategies in the management of myeloproliferative neoplasms


Co-Chairs

Jorge Cortes, MD
Jane and John Justin Distinguished Chair in Leukemia Research
Chief, CML & AML Sections
Deputy Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
 
Andre H. Goy, MD
Chairman and Executive Director
Lymphoma Division Chief - John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Professor of Medicine, Georgetown University
Hackensack, NJ
 
Sagar Lonial, MD, FACP
Professor, Emory School of Medicine
Chair, Department of Hematology & Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, GA







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By